Trace elements in glucometabolic disorders: An update

Diabetology and Metabolic Syndrome

Volumn 2, Issue 1, 2010, Pages

  Wiernsperger, Nicolas ^a   Rapin, Jeanrobert ^b  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CHROMIUM; GLUCOSE TRANSPORTER; GLYCOGEN; INSULIN RECEPTOR; LITHIUM; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; SELENIUM; SELENOPROTEIN; VANADIUM; ZINC;

ARTICLE; BONE LESION; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN METABOLISM; INSULIN RESISTANCE; KIDNEY INJURY; KNOWLEDGE; LIVER INJURY; LUNG CANCER; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; SUPPLEMENTATION; SWELLING; THEORY;

EID: 78650202507     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-2-70     Document Type: Article

References (176)

1. Implications of magnesium deficiency in type 2 diabetes: a review. DP Chaudhary R Sharma DD Bansal, Biol Trace Elem Res 2010 134 119 129 10.1007/s12011-009-8465-z 19629403
2. Evidence that the etiology of the syndrome containing type 2 diabetes mellitus results from abnormal magnesium metabolism. IC Wells, Can J Physiol Pharmacol 2008 86 16 24 10.1139/Y07-122 18418443
3. An inverse relationship between cumulating components of the metabolic syndrome and serum magnesium levels. AA Evangelopoulos NG Vallianou DB Panagiotakos A Georgiou GA Zacharias AN Alevra,, et al. Nutr Res 2008 28 659 663 10.1016/j.nutres.2008.07.001 19083473
4. Pathogenesis of insulin resistance in skeletal muscle. MA Abdul-Ghani RA DeFronzo, J Biomed Biotechnol 2010 476279 20445742
5. Dysregulation of Glycogen Synthase Kinase-3 in Skeletal Muscle and the Etiology of Insulin Resistance and Type 2 Diabetes. EJ Henriksen, Curr Diabetes Rev 2010 6 285 293 10.2174/157339910793360888 20594161
6. Diabetes, oxidative stress, nitric oxide and mitochondria function. M Friederich P Hansell F Palm, Curr Diabetes Rev 2009 5 120 144 10.2174/157339909788166800 19442097
7. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. H Kaneto N Katakami M Matsuhisa TA Matsuoka, Mediators Inflamm 2010 453892 20182627
8. Obesity, inflammation, and insulin resistance - a mini-review. M Zeyda TM Stulnig, Gerontology 2009 55 379 386 10.1159/000212758 19365105
9. Insulin signaling meets mitochondria in metabolism. Z Cheng Y Tseng MF White, Trends Endocrinol Metab 2010 21 589 598 10.1016/j.tem.2010.06.005 20638297
10. Trace element risk assessment: essentiality vs toxicity. SB Goldhaber, Regul Toxicol Pharmacol 2003 38 232 242 10.1016/S0273-2300(02)00020-X 14550763
11. Clinical and biochemical aspects of chromium deficiency. S Wallach, J Am Coll Nutr 1985 4 107 120 3886757
12. Prevalence of micronutrient deficiency in popular diet plans. JB Calton, J Int Soc Sports Nutr 2010 7 24 10.1186/1550-2783-7-24 20537171
13. Barley as high-chromium food. GS Mahdi, J Am Diet Assoc 1995 95 749 10.1016/S0002-8223(95)00206-5 7797801
14. Chemical properties and toxicity of chromium[III] nutritional supplements. A Levina PA Lay, Chem Res Toxicol 2008 21 563 571 10.1021/tx700385t 18237145
15. Chromium: celebrating 50 years as an essential element? JB Vincent, Dalton Trans 2010 39 3787 3794 10.1039/b920480f 20372701
16. Nutritional supplement chromium picolinate generates chromosomal aberrations and impedes progeny development in Drosophila melanogaster. DM Stallings DD Hepburn M Hannah JB Vincent J O'Donnell, Mutat Res 2006 610 101 113 16887379
17. A newly synthetic chromium complex-chromium [D-phenylalanine]3 activates AMP-activated protein kinase and stimulates glucose transport. P Zhao J Wang H Ma Y Xiao L He C Tong,, et al. Biochem Pharmacol 2009 77 1002 1010 10.1016/j.bcp.2008.11.018 19073152
18. Safety and toxicological evaluation of a novel chromium[III] dinicocysteinate complex. N Sreejayan PA Marone FC Lau T Yasmin M Bagchi D Bagchi, Toxicol Mech Methods 2010 20 321 333 10.3109/15376516.2010.487880 20515439
19. Use of chromium picolinate and biotin in the management of type 2 diabetes: an economic analysis. JP Fuhr Jr H He N Goldfarb DB Nash, Dis Manag 2005 8 265 275 10.1089/dis.2005.8.265 16117721
20. Effects of chromium picolinate on glucose uptake in insulin-resistant 3T3-L1 adipocytes involve activation of p38 MAPK. YQ Wang MH Yao, J Nutr Biochem 2009 20 982 991 10.1016/j.jnutbio.2008.09.002 19195868
21. Cellular chromium enhances activation of insulin receptor kinase. H Wang A Kruszewski DL Brautigan, Biochemistry 2005 44 8167 8175 10.1021/bi0473152 15924436
22. Chromium improves glucose uptake and metabolism through upregulating the mRNA levels of IR, GLUT4, GS, and UCP3 in skeletal muscle cells. W Qiao Z Peng Z Wang J Wei A Zhou, Biol Trace Elem Res 2009 131 133 142 10.1007/s12011-009- 8357-2 19283340
23. Chromium Improves Protein Deposition Through Regulating the mRNA Levels of IGF-1, IGF-1R, and Ub in Rat Skeletal Muscle Cells. Z Peng W Qiao Z Wang Q Dai J He C Guo,, et al. Biol Trace Elem Res 2010 137 226 234 10.1007/s12011-009-8579-3 20013160
24. Antidiabetogenic effects of chromium mitigate hyperinsulinemia-induced cellular insulin resistance via correction of plasma membrane cholesterol imbalance. EM Horvath L Tackett AM McCarthy P Raman JT Brozinick JS Elmendorf, Mol Endocrinol 2008 22 937 950 10.1210/me.2007-0410 18165437
25. Chromium picolinate positively influences the glucose transporter system via affecting cholesterol homeostasis in adipocytes cultured under hyperglycemic diabetic conditions. GR Pattar L Tackett P Liu JS Elmendorf, Mutat Res 2006 610 93 100 16870493
26. Chromium chloride inhibits oxidative stress and TNF-alpha secretion caused by exposure to high glucose in cultured U937 monocytes. SK Jain K Kannan, Biochem Biophys Res Commun 2001 289 687 691 10.1006/bbrc.2001.6026 11726202
27. Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNF-alpha, IL-6, CRP, glycated hemoglobin, triglycerides, and cholesterol levels in blood of streptozotocin-treated diabetic rats. SK Jain JL Rains JL Croad, Free Radic Biol Med 2007 43 1124 1131 10.1016/j. freeradbiomed.2007.05.019 17854708
28. Chromium picolinate inhibits resistin secretion in insulin-resistant 3T3-L1 adipocytes via activation of amp-activated protein kinase. YQ Wang Y Dong MH Yao, Clin Exp Pharmacol Physiol 2009 36 843 849 10.1111/j.1440-1681.2009. 05164.x 19298540
29. Chromium dinicocysteinate supplementation can lower blood glucose, CRP, MCP-1, ICAM-1, creatinine, apparently mediated by elevated blood vitamin C and adiponectin and inhibition of NFkappaB, Akt, and Glut-2 in livers of zucker diabetic fatty rats. SK Jain JL Croad T Velusamy JL Rains R Bull, Mol Nutr Food Res 2010 54 1371 1380 10.1002/mnfr.200900177 20306473
30. Molecular basis of chromium insulin interactions. R Sreekanth V Pattabhi SS Rajan, Biochem Biophys Res Commun 2008 369 725 729 10.1016/j.bbrc.2008.02.083 18307976
31. Copper, chromium, manganese, iron, nickel, and zinc levels in biological samples of diabetes mellitus patients. TG Kazi HI Afridi N Kazi MK Jamali MB Arain N Jalbani,, et al. Biol Trace Elem Res 2008 122 1 18 10.1007/s12011-007- 8062-y 18193174
32. Effect of insulin on radiochromium distribution in diabetic rats. JL Kraszeski S Wallach RL Verch, Endocrinology 1979 104 881 885 10.1210/endo-104-4-881 436761 (Pubitemid 9160697)
33. Chromium homeostasis in patients with type II [NIDDM] diabetes. BW Morris S MacNeil CA Hardisty S Heller C Burgin TA Gray, J Trace Elem Med Biol 1999 13 57 61 10445219
34. Chromium oligopeptide activates insulin receptor tyrosine kinase activity. CM Davis JB Vincent, Biochemistry 1997 36 4382 4385 10.1021/bi963154t 9109644
35. Isolation of a biologically active low-molecular-mass chromium compound from rabbit liver. A Yamamoto O Wada T Ono, Eur J Biochem 1987 65 627 631 10.1111/j.1432-1033.1987.tb11486.x (Pubitemid 17090845)
36. Chromium in human nutrition: a review. W Mertz, J Nutr 1993 123 626 633 8463863
37. Insulin sensitising action of chromium picolinate in various experimental models of diabetes mellitus. UA Shindea G Sharma YJ Xu NS Dhalla RK Goyal, J Trace Elem Med Biol 2004 18 23 32 10.1016/j.jtemb.2004.03.002 15487760
38. Effects of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men. MB Rabinowitz HC Gonick SR Levin MB Davidson, Diabetes Care 1983 6 319 327 10.2337/diacare.6.4.319 6352208
39. Effects of chromium histidinate on renal function, oxidative stress, and heat-shock proteins in fat-fed and streptozotocin-treated rats. A Dogukan M Tuzcu V Juturu G Cikim I Ozercan J Komorowski,, et al. J Ren Nutr 2010 20 112 120 10.1053/j.jrn.2009.04.009 19616452
40. Trivalent chromium inhibits protein glycosylation and lipid peroxidation in high glucose-treated erythrocytes. SK Jain P Patel K Rogier SK Jain, Antioxid Redox Signal 2006 8 238 241 10.1089/ars.2006.8.238 16487057
41. Effect of chromium supplementation on the diabetes induced-oxidative stress in liver and brain of adult rats. FM Refaie AY Esmat AF Mohamed WH Aboul Nour, Biometals 2009 19693677
42. Insulin-sensitizing and cholesterol-lowering effects of chromium [D-Phenylalanine]3. X Yang SY Li F Dong J Ren N Sreejayan, J Inorg Biochem 2006 100 1187 1193 10.1016/j.jinorgbio.2006.01.039 16545457
43. Dietary chromium decreases insulin resistance in rats fed a high-fat, mineral-imbalanced diet. JS Striffler MM Polansky RA Anderson, Metabolism 1998 47 396 400 10.1016/S0026-0495(98)90049-X 9550535
44. Chromium [D-phenylalanine]3 improves obesity-induced cardiac contractile defect in ob/ob mice. F Dong X Yang N Sreejayan J Ren, Obesity 2007 15 2699 2711 10.1038/oby.2007.322 18070761
45. Chromium picolinate supplementation improves insulin sensitivity in Goto-Kakizaki diabetic rats. DS Kim TW Kim JS Kang, J Trace Elem Med Biol 2004 17 243 247 10.1016/S0946-672X(04)80025-7 15139386
46. Effects of chromium picolinate supplementation on insulin sensitivity, serum lipids, and body weight in dexamethasone-treated rats. DS Kim TW Kim IK Park JS Kang AS Om, Metabolism 2002 51 589 594 10.1053/meta.2002.31985 11979390
47. Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic [JCR-LA corpulent] rats. WT Cefalu ZQ Wang XH Zhang LC Baldor JC Russell, J Nutr 2002 132 1107 1114 12042418
48. Insulin-sensitizing and cholesterol-lowering effects of chromium [D-Phenylalanine]3. X Yang SY Li F Dong J Ren N Sreejayan, J Inorg Biochem 2006 100 1187 1193 10.1016/j.jinorgbio.2006.01.039 16545457
49. Effects of chromium picolinate on glycemic control and kidney of the obese Zucker rat. MS Mozaffari R Abdelsayed JY Liu H Wimborne A El-Remessy A El-Marakby, Nutr Metab 2009 6 51 10.1186/1743-7075-6-51
50. Chromium[III] propionate and dietary fructans supplementation stimulate erythrocyte glucose uptake and beta-oxidation in lymphocytes of rats. T Kuryl Z Krejpcio RW Wojciak M Lipko B Debski H Staniek, Biol Trace Elem Res 2006 114 237 248 10.1385/BTER:114:1:237 17206006
51. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. J Martin ZQ Wang XH Zhang D Wachtel J Volaufova DE Matthews,, et al. Diabetes Care 2006 29 1826 1832 10.2337/dc06-0254 16873787 (Pubitemid 44156637)
52. The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized trial. GM Singer J Geohas, Diabetes Technol Ther 2006 8 636 643 10.1089/dia.2006.8.636 17109595
53. Antioxidant effects and insulin resistance improvement of chromium combined with vitamin C and E supplementation for type 2 diabetes mellitus. MH Lai, J Clin Biochem Nutr 2008 43 191 198 10.3164/jcbn.2008064 19015754
54. Glucose and insulin responses to dietary chromium supplements: a meta-analysis. MD Althuis NE Jordan EA Ludington JT Wittes, Am J Clin Nutr 2002 76 148 155 12081828
55. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. EM Balk A Tatsioni AH Lichtenstein J Lau AG Pittas, Diabetes Care 2007 30 2154 163 10.2337/dc06-0996 17519436
56. Clinical studies on chromium picolinate supplementation in diabetes mellitus - a review. CL Broadhurst P Domenico, Diabetes Technol Ther 2006 8 677 687 10.1089/dia.2006.8.677 17109600
57. Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation. ZQ Wang J Qin J Martin XH Zhang O Sereda RA Anderson,, et al. Metabolism 2007 56 1652 1655 10.1016/j.metabol. 2007.07.007 17998017
58. Current concepts about chromium supplementation in type 2 diabetes and insulin resistance. ZQ Wang WT Cefalu, Curr Diab Rep 2010 10 145 151 10.1007/s11892-010-0097-3 20425574
59. Effect of chromium on the insulin resistance in patients with type II diabetes mellitus. SV Vladeva DD Terzieva DT Arabadjiiska, Folia Med 2005 47 59 62
60. Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome. ML Lydic M McNurlan S Bembo L Mitchell E Komaroff M Gelato, Fertil Steril 2005 86 243 246 10.1016/j.fertnstert.2005.11.069
61. Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults. N Iqbal S Cardillo S Volger LT Bloedon RA Anderson R Boston,, et al. Metab Syndr Relat Disord 2009 7 143 150 10.1089/met.2008.0048 19422140
62. Zinc supplementation for the treatment or prevention of disease: current status and future perspectives. H Haase S Overbeck L Rink, Exp Gerontol 2008 43 394 408 10.1016/j.exger.2007.12.002 18221847
63. Zinc prevents the structural and functional properties of free radical treated-insulin. P Faure JL Lafond C Coudray E Rossini S Halimi A Favier,, et al. Biochim Biophys Acta 1994 1209 260 264 10.1016/0167-4838(94)90194-5 7811700
64. Zinc: an essential micronutrient. RB Saper R Rash, Am Fam Physician 2009 79 768 772 20141096
65. Zinc: health effects and research priorities for the 1990s. CT Walsh HH Sandstead AS Prasad PM Newberne PJ Fraker, Environ Health Perspect 1994 102 Suppl 2 5 46 10.2307/3431820 7925188
66. Zinc requirements and the risks and benefits of zinc supplementation. W Maret HH Sandstead, J Trace Elem Med Biol 2006 20 3 18 10.1016/j.jtemb.2006.01. 006 16632171
67. Methods of assessment of zinc status in humans: a systematic review. NM Lowe K Fekete T Decsi, Am J Clin Nutr 2009 89 2040S 2051S 10.3945/ajcn.2009. 27230G 19420098
68. Mechanism and regulation of cellular zinc transport. I Sekler SL Sensi M Hershfinkel WF Silverman, Mol Med 2007 13 337 343 10.2119/2007-00037.Sekler 17622322
69. Mammalian zinc transporters. JP Liuzzi RJ Cousins, Annu Rev Nutr 2004 24 151 172 10.1146/annurev.nutr.24.012003.132402 15189117
70. Mammalian zinc transporters: nutritional and physiologic regulation. LA Lichten RJ Cousins, Annu Rev Nutr 2009 29 153 176 10.1146/annurev-nutr-033009- 083312 19400752
71. Zinc fluxes and zinc transporter genes in chronic diseases. C Devirgiliis PD Zalewski G Perozzi C Murgia, Mutat Res 2007 62 84 93
72. Zinc, zinc transporters and diabetes. J Rungby, Diabetologia 2010 53 1549 51 10.1007/s00125-010-1793-x 20490449
73. Zinc, a regulator of islet function and glucose homeostasis. N Wijesekara F Chimienti MB Wheeler, Diabetes Obes Metab 2009 11 Suppl 4 202 214 10.1111/j.1463-1326.2009.01110.x 19817803
74. Clinical, immunological, anti-inflammatory and antioxidant roles of zinc. AS Prasad, Exp Gerontol 2008 43 370 377 10.1016/j.exger.2007.10.013 18054190
75. Oxidative stress as a therapeutic target in diabetes: revisiting the controversy. NF Wiernsperger, Diabetes Metab 2003 29 579 585 10.1016/S1262-3636(07)70072-1 14707886
76. Status of essential trace metals in biological samples of diabetic mother and their neonates. HI Afridi TG Kazi N Kazi JA Baig MK Jamali MB Arain,, et al. Arch Gynecol Obstet 2009 280 415 423 10.1007/s00404-009-0955-x 19169697
77. Current zinc intake and risk of diabetes and coronary artery disease and factors associated with insulin resistance in rural and urban populations of North India. RB Singh MA Niaz SS Rastogi S Bajaj Z Gaoli Z Shoumin, J Am Coll Nutr 1998 17 564 570 9853535
78. Altered metabolism of copper, zinc, and magnesium is associated with increased levels of glycated hemoglobin in patients with diabetes mellitus. A Viktorinova E Toserova M Krizko Z Durackova, Metabolism 2009 58 1477 1482 10.1016/j.metabol.2009.04.035 19592053
79. Trace and toxic element patterns in nonsmoker patients with noninsulin-dependent diabetes mellitus, impaired glucose tolerance, and fasting glucose. MA Serdar F Bakir A Hasimi T Celik O Akin L Kenar,, et al. Int J Diabetes Dev Ctries 2009 29 35 40 10.4103/0973-3930.50713 20062562
80. Copper, zinc, and magnesium levels in non-insulin dependent diabetes mellitus. AH Zargar NA Shah SR Masoodi BA Laway FA Dar AR Khan,, et al. Postgrad Med J 1998 74 665 668 10.1136/pgmj.74.877.665 10197198
81. Zinc, insulin and diabetes. AB Chausmer, J Am Coll Nutr 1998 17 109 115 9550453
82. Dietary intake and serum and hair concentrations of minerals and their relationship with serum lipids and glucose levels in hypertensive and obese patients with insulin resistance. J Suliburska P Bogdanski D Pupek-Musialik Z Krejpcio, Biol Trace Elem Res 20195917
83. Plasma copper, zinc, and selenium levels and correlates with metabolic syndrome components of lebanese adults. O Obeid M Elfakhani S Hlais M Iskandar M Batal Y Mouneimne,, et al. Biol Trace Elem Res 2008 123 58 65 10.1007/s12011-008-8112-0 18288450
84. Plasma mineral content in type-2 diabetic patients and their association with the metabolic syndrome. MV Aguilar P Saavedra FJ Arrieta CJ Mateos MJ Gonzalez I Meseguer,, et al. Ann Nutr Metab 2007 51 402 406 10.1159/000108108 17851234
85. Serum zinc level and coronary heart disease events in patients with type 2 diabetes. M Soinio J Marniemi M Laakso K Pyorala S Lehto T Ronnemaa, Diabetes Care 2007 30 523 528 10.2337/dc06-1682 17327315
86. Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. R Ilouz O Kaidanovich D Gurwitz H Eldar-Finkelman, Biochem Biophys Res Commun 2002 295 102 106 10.1016/S0006-291X(02)00636-8 12083774
87. Zinc and diabetes - clinical links and molecular mechanisms. J Jansen W Karges L Rink, J Nutr Biochem 2009 20 399 417 10.1016/j.jnutbio.2009.01.009 19442898
88. Antioxidant effect of zinc in humans. AS Prasad B Bao FW Beck O Kucuk FH Sarkar, Free Radic Biol Med 2004 37 1182 1190 10.1016/j.freeradbiomed.2004.07. 007 15451058
89. Zinc signalling and subcellular distribution: emerging targets in type 2 diabetes. E Mocchegiani R Giacconi M Malavolta, Trends Mol Med 2008 14 419 428 10.1016/j.molmed.2008.08.002 18774338
90. Zinc and selenium, site-specific versus general antioxidation. WJ Bettger, Can J Physiol Pharmacol 1993 71 721 724 8313237
91. Zinc and redox signaling: perturbations associated with cardiovascular disease and diabetes mellitus. M Foster S Samman, Antioxid Redox Signal 2010 13 1549 1573 10.1089/ars.2010.3111 20568953
92. The function of zinc metallothionein: a link between cellular zinc and redox state. W Maret, J Nutr 2000 130 5S Suppl 1455S 8S 10801959
93. Effect of different dietary zinc levels on hepatic antioxidant and micronutrients indices under oxidative stress conditions. RS Tupe SG Tupe KV Tarwadi VV Agte, Metabolism 2010 59 1603 1611 10.1016/j.metabol.2010.02.020 20359724
94. Low micromolar zinc exerts cytotoxic action under H[2]O[2]-induced oxidative stress: Excessive increase in intracellular Zn[2+] concentration. H Matsui TM Oyama Y Okano E Hashimoto T Kawanai Y Oyama, Toxicology 2010 276 27 32 10.1016/j.tox.2010.06.011 20603178
95. Why have antioxidants failed in clinical trials? SR Steinhubl, Am J Cardiol 2008 101 14D 19D 10.1016/j.amjcard.2008.02.003 18474268
96. Oxidative stress: the special case of diabetes. NF Wiernsperger, Biofactors 2003 19 11 18 10.1002/biof.5520190103 14757973
97. Prenatal and perinatal zinc restriction: effects on body composition, glucose tolerance and insulin response in rat offspring. IJ Padmavathi YD Kishore L Venu M Ganeshan N Harishankar NV Giridharan,, et al. Exp Physiol 2009 94 761 769 10.1113/expphysiol.2008.045856 19251982
98. Dietary zinc supplementation attenuates hyperglycemia in db/db mice. SF Simon CG Taylor, Exp Biol Med 2001 226yang 43 51
99. Zinc supplementation partially prevents renal pathological changes in diabetic rats. Y Tang Q Yang J Lu X Zhang D Suen Y Tan,, et al. J Nutr Biochem 2010 21 237 246 10.1016/j.jnutbio.2008.12.010 19369054
100. Dietary zinc restriction in rats alters antioxidant status and increases plasma F2 isoprostanes. RS Bruno Y Song SW Leonard DJ Mustacich AW Taylor MG Traber,, et al. J Nutr Biochem 2007 18 509 518 10.1016/j.jnutbio.2006.09.001 17142032
101. Long term excessive Zn-supplementation promotes metabolic syndrome-X in Wistar rats fed sucrose and fat rich semisynthetic diet. SK Taneja R Mandal S Girhotra, Indian J Exp Biol 2006 44 705 718 16999025
102. Modulation of Zn-induced hyperinsulinemia/insulin resistance in Wistar rat fed modified poultry egg. SK Taneja R Mandal, Biofactors 2009 35 389 398 10.1002/biof.51 19565473
103. Prospective study of zinc intake and risk of type 2 diabetes in women. Q Sun RM van Dam WC Willett FB Hu, Diabetes Care 2009 32 629 634 10.2337/dc08-1913 19171718
104. The influence of zinc supplementation on glucose homeostasis in NIDDM. I Raz D Karsai M Katz, Diabetes Res 1989 11 73 79 2695282
105. Effect of zinc supplementation on serum homocysteine in type 2 diabetic patients with microalbuminuria. E Heidarian M Amini M Parham A Aminorroaya, Rev Diabet Stud 2009 6 64 70 10.1900/RDS.2009.6.64 19557297
106. Effect of zinc supplementation on serum leptin levels and insulin resistance of obese women. DN Marreiro B Geloneze MA Tambascia AC Lerario A Halpern SM Cozzolino, Biol Trace Elem Res 2006 112 109 118 10.1385/BTER:112:2: 109 17028377
107. Zinc supplementation for the prevention of type 2 diabetes mellitus. V Beletate RP El Dib AN Atallah, Cochrane Database Syst Rev 2007 D005525 17253560
108. Effects of zinc supplementation on antioxidant enzyme activities in healthy old subjects. E Mariani F Mangialasche FT Feliziani R Cecchetti M Malavolta P Bastiani,, et al. Exp Gerontol 2008 43 445 451 10.1016/j.exger.2007. 10.012 18078731
109. Antidiabetic properties of zinc-alpha2-glycoprotein in ob/ob mice. ST Russell MJ Tisdale, Endocrinology 2010 151 948 957 10.1210/en.2009-0827 20032055
110. Lower zinc-alpha2-glycoprotein production by adipose tissue and liver in obese patients unrelated to insulin resistance. DM Selva A Lecube C Hernandez JA Baena JM Fort R Simo, J Clin Endocrinol Metab 2009 94 4499 4507 10.1210/jc.2009-0758 19622624
111. Oral administration of a zinc complex improves type 2 diabetes and metabolic syndromes. Y Adachi J Yoshida Y Kodera T Kiss T Jakusch EA Enyedy,, et al. Biochem Biophys Res Commun 2006 351 165 170 10.1016/j.bbrc.2006.10.014 17052688
112. A new type of orally active anti-diabetic Zn[II]-dithiocarbamate complex. Y Yoshikawa Y Adachi H Sakurai, Life Sci 2007 80 759 766 10.1016/j.lfs.2006.11. 003 17137606
113. Selenium in food and the human body: a review. M Navarro-Alarcon C Cabrera-Vique, Sci Total Environ 2008 400 115 141 10.1016/j.scitotenv.2008.06. 024 18657851
114. Protection against reactive oxygen species by selenoproteins. H Steinbrenner H Sies, Biochim Biophys Acta 2009 1790 1478 85 19268692
115. Selenoproteins. J Lu A Holmgren, J Biol Chem 2009 284 723 727 10.1074/jbc.R800045200 18757362
116. Selenoprotein metabolism and function: evidence for more than one function for selenoprotein P. RF Burk KE Hill AK Motley, J Nutr 2003 133 5 Suppl 1 1517S 20S 12730456
117. The diverse role of selenium within selenoproteins: a review. DH Holben AM Smith, J Am Diet Assoc 1999 99 836 843 10.1016/S0002-8223(99)00198-4 10405682
118. Selenium levels in first-degree relatives of diabetic patients. M Ozkaya M Sahin E Cakal K Gisi F Bilge M Kilinc, Biol Trace Elem Res 2009 128 144 151 10.1007/s12011-008-8263-z 18979071
119. High selenium may be a risk factor of adolescent idiopathic scoliosis. Z Yang Y Xie J Chen D Zhang C Yang M Li, Med Hypotheses 2010 75 126 127 10.1016/j.mehy.2010.02.006 20189316
120. Risk of chronic low-dose selenium overexposure in humans: insights from epidemiology and biochemistry. M Vinceti T Maraldi M Bergomi C Malagoli, Rev Environ Health 2009 24 231 248 19891121
121. Selenium as a 'nutraceutical': how to conciliate physiological and supra-nutritional effects for an essential trace element. J Neve, Curr Opin Clin Nutr Metab Care 2002 5 659 663 10.1097/00075197-200211000-00008 12394641
122. Antioxidant activity of sulfur and selenium: a review of reactive oxygen species scavenging, glutathione peroxidase, and metal-binding antioxidant mechanisms. EE Battin JL Brumaghim, Cell Biochem Biophys 2009 55 1 23 10.1007/s12013-009-9054-7 19548119
123. The antioxidant role of selenium and seleno-compounds. H Tapiero DM Townsend KD Tew, Biomed Pharmacother 2003 57 134 144 10.1016/S0753-3322(03) 00035-0 12818475
124. Selenium inhibits high glucose- and high insulin-induced adhesion molecule expression in vascular endothelial cells. HT Zheng LN Zhou CJ Huang X Hua R Jian BH Su,, et al. Arch Med Res 2008 39 373 379 10.1016/j.arcmed.2007.12. 007 18375247
125. Selenium and inflammation: underlying anti-inflammatory mechanisms. LH Duntas, Horm Metab Res 2009 41 443 447 10.1055/s-0029-1220724 19418416
126. Selenium treatment protects diabetes-induced biochemical and ultrastructural alterations in liver tissue. B Can NN Ulusu K Kilinc N Leyla Acan Y Saran B Turan, Biol Trace Elem Res 2005 105 135 150 10.1385/BTER:105:1-3: 135 16034159
127. Effects of selenium supplementation on antioxidant defense and glucose homeostasis in experimental diabetes mellitus. Z Erbayraktar O Yilmaz AT Artmann R Cehreli C Coker, Biol Trace Elem Res 2007 118 217 226 10.1007/s12011-007- 0037-5 17916924
128. Nutritional selenium supplements: product types, quality, and safety. GN Schrauzer, J Am Coll Nutr 2001 20 1 4 11293463
129. Compendium of the antidiabetic effects of supranutritional selenate doses. In vivo and in vitro investigations with type II diabetic db/db mice. AS Mueller J Pallauf, J Nutr Biochem 2006 17 548 560 10.1016/j.jnutbio.2005.10.006 16443359
130. Dietary selenium intake is negatively associated with serum sialic acid and metabolic syndrome features in healthy young adults. MA Zulet B Puchau HH Hermsdorff C Navarro JA Martinez, Nutr Res 2009 29 41 48 10.1016/j.nutres.2008. 11.003 19185776
131. Selenium intake reduces serum C3, an early marker of metabolic syndrome manifestations, in healthy young adults. B Puchau MA Zulet A Gonzalez de Echavarri I Navarro-Blasco JA Martinez, Eur J Clin Nutr 2009 63 858 864 10.1038/ejcn.2008.48 18985060
132. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. S Stranges JR Marshall R Natarajan RP Donahue M Trevisan GF Combs,, et al. Ann Intern Med 2007 147 217 223 17620655
133. Serum selenium and diabetes in U.S. adults. J Bleys A Navas-Acien E Guallar, Diabetes Care 2007 30 829 834 10.2337/dc06-1726 17392543
134. Serum selenium concentrations and hypertension in the US Population. M Laclaustra A Navas-Acien S Stranges JM Ordovas E Guallar, Circ Cardiovasc Qual Outcomes 2009 2 :369 376 10.1161/CIRCOUTCOMES.108.831552 20031863
135. Selenium or no selenium - that is the question in tumor patients: a new controversy. R Muecke L Schomburg J Buentzel K Kisters O Micke, Integr Cancer Ther 2010 9 136 141 10.1177/1534735410367648 20462857
136. Vanadium in diabetes: 100 years from Phase 0 to Phase I. KH Thompson C Orvig, J Inorg Biochem 2006 100 1925 1935 10.1016/j.jinorgbio.2006.08.016 17055061
137. Anti-diabetic and toxic effects of vanadium compounds. AK Srivastava, Mol Cell Biochem 2000 206 177 182 10.1023/A:1007075204494 10839208
138. Vanadium and tungsten derivatives as antidiabetic agents: a review of their toxic effects. JL Domingo, Biol Trace Elem Res 2002 88 97 112 10.1385/BTER:88:2:097 12296430
139. Vanadium compounds induced mitochondria permeability transition pore [PTP] opening related to oxidative stress. Y Zhao L Ye H Liu Q Xia Y Zhang X Yang,, et al. J Inorg Biochem 2010 104 371 378 10.1016/j.jinorgbio.2009.11.007 20015552
140. A review of current toxicological concerns on vanadium pentoxide and other vanadium compounds: gaps in knowledge and directions for future research. FL Assem LS Levy, J Toxicol Environ Health B Crit Rev 2009 12 289 306 20183524
141. Insulin signal mimicry as a mechanism for the insulin-like effects of vanadium. MZ Mehdi SK Pandey JF Theberge AK Srivastava, Cell Biochem Biophys 2006 44 73 81 10.1385/CBB:44:1:073 16456236
142. Bis[maltolato]-oxovanadium [IV]-induced phosphorylation of PKB, GSK-3 and FOXO1 contributes to its glucoregulatory responses. G Vardatsikos MZ Mehdi AK Srivastava, Int J Mol Med 2009 24 303 309 19639221
143. Insulin-like effects of vanadate on glucokinase activity and fructose 2,6-bisphosphate levels in the liver of diabetic rats. J Gil M Miralpeix J Carreras R Bartrons, J Biol Chem 1988 263 1868 1871 2828354
144. Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil. E Shafrir S Spielman I Nachliel M Khamaisi H Bar-On E Ziv, Diabetes Metab Res Rev 2001 17 55 66 10.1002/1520-7560(2000)9999:9999<::AID-DMRR165>3.0.CO;2-J 11241892
145. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. M Halberstam N Cohen P Shlimovich L Rossetti H Shamoon, Diabetes 1996 45 659 666 10.2337/diabetes.45.5.659 8621019
146. Effect of vanadium on insulin sensitivity in patients with impaired glucose tolerance. O Jacques-Camarena M Gonzalez-Ortiz E Martinez-Abundis JF Lopez-Madrueno R Medina-Santillan, Ann Nutr Metab 2008 53 195 198 10.1159/000175844 19033682
147. Vanadium and diabetes. P Poucheret S Verma MD Grynpas JH McNeill, Mol Cell Biochem 1998 188 73 80 10.1023/A:1006820522587 9823013
148. Oral insulin-mimetic compounds that act independently of insulin. S Garcia-Vicente F Yraola L Marti E Gonzalez-Munoz MJ Garcia-Barrado C Canto,, et al. Diabetes 2007 56 486 493 10.2337/db06-0269 17259395
149. Arylalkylamine vanadium salts as new anti-diabetic compounds. A Zorzano M Palacin L Marti S Garcia-Vicente, J Inorg Biochem 2009 103 559 566 10.1016/j.jinorgbio.2009.01.015 19246098
150. A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus. DM Smith RM Pickering GT Lewith, QJM 2008 101 351 358 10.1093/qjmed/hcn003 18319296
151. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. G Boden X Chen J Ruiz GD van Rossum S Turco, Metabolism 1996 45 1130 1135 10.1016/S0026-0495(96)90013-X 8781301
152. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. N Cohen M Halberstam P Shlimovich CJ Chang H Shamoon L Rossetti, J Clin Invest 1995 95 2501 2509 10.1172/JCI117951 7769096
153. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. AB Goldfine ME Patti L Zuberi BJ Goldstein R LeBlanc EJ Landaker,, et al. Metabolism 2000 49 400 410 10.1016/S0026-0495(00)90418-9 10726921
154. Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. K Cusi S Cukier RA DeFronzo M Torres FM Puchulu JC Redondo, J Clin Endocrinol Metab 2001 86 1410 1417 10.1210/jc.86.3.1410 11238540
155. Vanadium treatment of type 2 diabetes: a view to the future. KH Thompson J Lichter C LeBel MC Scaife JH McNeill C Orvig, J Inorg Biochem 2009 103 554 558 10.1016/j.jinorgbio.2008.12.003 19162329
156. Lithium: clinical considerations in internal medicine. MP Freeman SA Freeman, Am J Med 2006 119 478 481 10.1016/j.amjmed.2005.11.003 16750958
157. Lithium: a review of its metabolic adverse effects. C Livingstone H Rampes, J Psychopharmacol 2006 20 347 355 10.1177/0269881105057515 16174674
158. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. RS Jope, Trends Pharmacol Sci 2003 24 441 443 10.1016/S0165-6147(03) 00206-2 12967765
159. Validating GSK3 as an in vivo target of lithium action. WT O'Brien PS Klein, Biochem Soc Trans 2009 37 Pt 5 1133 1138 19754466
160. Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats. EJ Henriksen TR Kinnick MK Teachey MP O'Keefe D Ring KW Johnson,, et al. Am J Physiol Endocrinol Metab 2003 284 892 E900 12517738
161. The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. O Kaidanovich H Eldar-Finkelman, Expert Opin Ther Targets 2002 6 555 561 10.1517/14728222.6.5.555 12387679
162. The control of glycogen metabolism in the liver. HG Hers, Annu Rev Biochem 1976 45 167 189 10.1146/annurev.bi.45.070176.001123 183599
163. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. TD Gould CA Zarate HK Manji, J Clin Psychiatry 2004 65 10 21 10.4088/JCP.v65n0103 14744163
164. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. JG Fiedorowicz NM Palagummi VL Forman-Hoffman DD Miller WG Haynes, Ann Clin Psychiatry 2008 20 131 137 18633739
165. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. A Sicras J Rejas R Navarro J Serrat M Blanca, Bipolar Disord 2008 10 607 616 10.1111/j.1399-5618.2008.00599.x 18657245
166. Transient diabetes associated with withdrawal of lithium therapy. OE Okosieme A Campbell K Patton ML Evans, Diabetes Care 2006 29 1181 10.2337/dc06-0291 16644668
167. Roles of insulin signalling and p38 MAPK in the activation by lithium of glucose transport in insulin-resistant rat skeletal muscle. AR Macko AN Beneze MK Teachey EJ Henriksen, Arch Physiol Biochem 2008 114 331 339 10.1080/13813450802536067 19023684
168. Essential role of p38 MAPK for activation of skeletal muscle glucose transport by lithium. NB Harrell MK Teachey NJ Gifford EJ Henriksen, Arch Physiol Biochem 2007 113 221 227 10.1080/13813450701783158 18158645
169. Effect of lithium on plasma glucose, insulin and glucagon in normal and streptozotocin-diabetic rats: role of glucagon in the hyperglycaemic response. OG Hermida T Fontela M Ghiglione LO Uttenthal, Br J Pharmacol 1994 111 861 865 8019763
170. Lithium's effects on rat liver glucose metabolism in vivo. JE Rodriguez-Gil JM Fernandez-Novell A Barbera JJ Guinovart, Arch Biochem Biophys 2000 375 377 384 10.1006/abbi.1999.1679 10700396
171. Nutritional supplementation for type 2 diabetes: a systematic review. HE Bartlett F Eperjesi, Ophthalmic Physiol Opt 2008 28 503 523 10.1111/j.1475-1313. 2008.00595.x 19076553
172. Protective effects of combined micronutrients on islet beta-cells of streptozotocin-induced diabetic mice. Y Chang GZ Zhang SL Piao S Gao DM Zheng Y Song,, et al. Int J Vitam Nutr Res 2009 79 104 116 10.1024/0300-9831.79.2.104 20108212
173. Comparison of the effects of zinc alone and zinc associated with selenium and vitamin E on insulin sensitivity and oxidative stress in high-fructose-fed rats. P Faure D Barclay M Joyeux-Faure S Halimi, J Trace Elem Med Biol 2007 21 113 119 10.1016/j.jtemb.2006.12.005 17499151
174. Chronic maternal dietary chromium restriction modulates visceral adiposity: probable underlying mechanisms. IJ Padmavathi KR Rao L Venu M Ganeshan KA Kumar N Rao Ch,, et al. Diabetes 2010 59 98 104 10.2337/db09-0779 19846803
175. Maternal dietary chromium restriction programs muscle development and function in the rat offspring. IJ Padmavathi KR Rao L Venu A Ismail M Raghunath, Exp Biol Med 2010 235 349 355 10.1258/ebm.2009.009199
176. Does maternal dietary mineral restriction per se predispose the offspring to insulin resistance? L Venu N Harishankar TP Krishna M Raghunath, Eur J Endocrinol 2004 151 287 294 10.1530/eje.0.1510287 15296486